Librela

RSS

bedinvetmab

Authorised
This medicine is authorised for use in the European Union.

Overview

Librela is a veterinary medicine used for the alleviation of pain associated with osteoarthritis in dogs. It contains the active substance bedinvetmab.

This EPAR was last updated on 21/02/2022

Authorisation details

Product details
Name
Librela
Agency product number
EMEA/V/C/005180
Active substance
bedinvetmab
International non-proprietary name (INN) or common name
bedinvetmab
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QN02B
Publication details
Marketing-authorisation holder
Zoetis Belgium SA 
Revision
1
Date of issue of marketing authorisation valid throughout the European Union
10/11/2020
Contact address

Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

Product information

18/02/2022 Librela - EMEA/V/C/005180 - IB-0003

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Analgesics

Therapeutic indication

For the alleviation of pain associated with osteoarthritis in dogs

Assessment history

How useful was this page?

Add your rating
Average
20 ratings
8 ratings
1 rating
2 ratings